Psoriasis is a common inflammatory disorder with potentially severe systemic and dermatologic consequences. As traditional treatments for this condition fail, biologics are emerging as the next promising therapy for moderate-to-severe cases, especially for the lower extremity. This review examines current research on monoclonal antibodies that target specific cytokines including interleukin-23 (IL-23), IL-12, tumor necrosis factor alpha, and IL-17 involved in pathologic inflammatory processes.
Keywords: Biologics; Cytokine; Inflammatory; Interleukin; Monoclonal antibodies; Psoriasis.
Copyright © 2021 Elsevier Inc. All rights reserved.